Briony Larance1, Nicholas Lintzeris2, Raimondo Bruno3, Amy Peacock3, Elena Cama4, Robert Ali5, Ivana Kihas4, Antonia Hordern4, Nancy White5, Louisa Degenhardt6. 1. National Drug and Alcohol Research Centre, UNSW, NSW, Australia. Electronic address: b.larance@unsw.edu.au. 2. Sydney Medical School, Sydney University, NSW, Australia; The Langton Centre, South East Sydney Local Health District (SESLHD) Drug and Alcohol Services, NSW, Australia. 3. School of Medicine, University of Tasmania, Tasmania, Australia. 4. National Drug and Alcohol Research Centre, UNSW, NSW, Australia. 5. University of Adelaide, South Australia, Australia. 6. National Drug and Alcohol Research Centre, UNSW, NSW, Australia; School of Population and Global Health, University of Melbourne, Victoria, Australia; Murdoch Children's Research Institute, Australia; Department of Global Health, School of Public Health, University of WA, USA.
Abstract
AIMS: To describe the methods and baseline characteristics of a cohort of people who tamper with pharmaceutical opioids, formed to examine changes in opioid use following introduction of Reformulated OxyContin®. METHODS: Participants were 606 people from three Australian jurisdictions who reported past month injecting, snorting, chewing or smoking of a pharmaceutical opioid and had engaged in these practices at least monthly in the past 6 months. Baseline interviews were conducted prior to introduction of Reformulated OxyContin® in April 2014. Patterns of opioid use and cohort characteristics were examined according to whether participants were prescribed opioid medications, or exclusively used diverted medication. RESULTS: The cohort reported high levels of moderate/severe depression (61%), moderate/severe anxiety (43%), post-traumatic stress disorder (42%), chronic pain or disability (past 6 months, 54%) and pain (past month, 47%). Lifetime use of oxycodone, morphine, opioid substitution medications and codeine were common. Three-quarters (77%) reported ICD-10 lifetime pharmaceutical opioid dependence and 40% current heroin dependence. Thirteen percent reported past year overdose, and 70% reported at least one past month opioid injection-related injury or disease. The cohort displayed complex clinical profiles, but participants currently receiving opioid substitution therapy who were also prescribed other opioids particularly reported a wide range of risk behaviors, despite their health service engagement. CONCLUSIONS: Findings highlight the heterogeneity in the patterns and clinical correlates of opioid use among people who tamper with pharmaceutical opioids. Targeted health interventions are essential to reduce the associated harms.
AIMS: To describe the methods and baseline characteristics of a cohort of people who tamper with pharmaceutical opioids, formed to examine changes in opioid use following introduction of Reformulated OxyContin®. METHODS:Participants were 606 people from three Australian jurisdictions who reported past month injecting, snorting, chewing or smoking of a pharmaceutical opioid and had engaged in these practices at least monthly in the past 6 months. Baseline interviews were conducted prior to introduction of Reformulated OxyContin® in April 2014. Patterns of opioid use and cohort characteristics were examined according to whether participants were prescribed opioid medications, or exclusively used diverted medication. RESULTS: The cohort reported high levels of moderate/severe depression (61%), moderate/severe anxiety (43%), post-traumatic stress disorder (42%), chronic pain or disability (past 6 months, 54%) and pain (past month, 47%). Lifetime use of oxycodone, morphine, opioid substitution medications and codeine were common. Three-quarters (77%) reported ICD-10 lifetime pharmaceutical opioid dependence and 40% current heroin dependence. Thirteen percent reported past year overdose, and 70% reported at least one past month opioid injection-related injury or disease. The cohort displayed complex clinical profiles, but participants currently receiving opioid substitution therapy who were also prescribed other opioids particularly reported a wide range of risk behaviors, despite their health service engagement. CONCLUSIONS: Findings highlight the heterogeneity in the patterns and clinical correlates of opioid use among people who tamper with pharmaceutical opioids. Targeted health interventions are essential to reduce the associated harms.
Authors: Andrea L Schaffer; Nicholas A Buckley; Louisa Degenhardt; Briony Larance; Rose Cairns; Timothy A Dobbins; Sallie-Anne Pearson Journal: CMAJ Date: 2018-03-26 Impact factor: 8.262
Authors: Gregory Eigner; Brian Henriksen; Philip Huynh; David Murphy; Christopher Brubaker; Jana Sanders; Deborah McMahan Journal: Health Serv Res Manag Epidemiol Date: 2017-09-08
Authors: Natasa Gisev; Sallie-Anne Pearson; Timothy Dobbins; David C Currow; Fiona Blyth; Sarah Larney; Adrian Dunlop; Richard P Mattick; Andrew Wilson; Louisa Degenhardt Journal: BMJ Open Date: 2018-12-04 Impact factor: 2.692